We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

114 hedge funds and large institutions have $423M invested in Concert Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 37 increasing their positions, 23 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

327% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 11

93% more capital invested

Capital invested by funds: $219M → $423M (+$204M)

61% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 23

59% more call options, than puts

Call options by funds: $1.22M | Put options by funds: $769K

44% more funds holding

Funds holding: 79 → 114 (+35)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
114
Holders Change
+35
Holders Change %
+44.3%
% of All Funds
2.59%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
47
Increased
37
Reduced
23
Closed
11
Calls
$1.22M
Puts
$769K
Net Calls
+$452K
Net Calls Change
+$80K

Top Buyers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
+$14.3M
2
BlackRock
BlackRock
New York
+$13.1M
3
Millennium Management
Millennium Management
New York
+$10.1M
4
BC
Boxer Capital
California
+$8.05M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$6M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$26.9M
2
BI
BVF Inc
California
-$23.5M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$5.43M
4
LSC
Lyon Street Capital
California
-$5.21M
5
SM
Senvest Management
New York
-$4.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
51
Invesco
Georgia
$1.27M +$642K +31,890 +183%
State of New Jersey Common Pension Fund D
52
State of New Jersey Common Pension Fund D
New Jersey
$1.03M – – –
EGI
53
EAM Global Investors
California
$1.02M +$792K +39,327 New
FQ
54
First Quadrant
California
$978K +$761K +37,814 New
DCM
55
Dupont Capital Management
Delaware
$970K +$755K +37,494 New
PAM
56
Panagora Asset Management
Massachusetts
$963K +$749K +37,220 New
Charles Schwab
57
Charles Schwab
California
$948K +$90.6K +4,499 +14%
EI
58
EAM Investors
California
$903K +$703K +34,905 New
Russell Investments Group
59
Russell Investments Group
United Kingdom
$760K +$592K +29,378 New
PPA
60
Parametric Portfolio Associates
Washington
$739K +$361K +17,947 +169%
California State Teachers Retirement System (CalSTRS)
61
California State Teachers Retirement System (CalSTRS)
California
$731K -$4.43K -220 -0.8%
SO
62
STRS Ohio
Ohio
$724K +$564K +28,000 New
Swiss National Bank
63
Swiss National Bank
Switzerland
$719K – – –
CIP
64
Convergence Investment Partners
Florida
$718K +$559K +27,750 New
FDCDDQ
65
Federation des caisses Desjardins du Quebec
Quebec, Canada
$650K +$507K +25,194 New
AA
66
ALPS Advisors
Colorado
$650K +$56.3K +2,796 +13%
New York State Common Retirement Fund
67
New York State Common Retirement Fund
New York
$624K +$160K +7,931 +49%
CS
68
Credit Suisse
Switzerland
$605K +$196K +9,726 +71%
Federated Hermes
69
Federated Hermes
Pennsylvania
$567K +$441K +21,923 New
Wellington Management Group
70
Wellington Management Group
Massachusetts
$558K +$434K +21,540 New
Barclays
71
Barclays
United Kingdom
$534K +$256K +12,700 +159%
MCM
72
Manchester Capital Management
Vermont
$517K – – –
Squarepoint
73
Squarepoint
New York
$498K -$45K -2,237 -10%
CSS
74
Cubist Systematic Strategies
Connecticut
$474K +$274K +13,595 +287%
First Manhattan
75
First Manhattan
New York
$463K -$1.03M -51,000 -74%
1 2
3
4 5

CNCE Hedge Fund Activity: Q4 2017 in Review

114 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2017, worth a combined $423M — up 93% from $219M a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new CNCE positions and 11 closed out — a net gain of 36 holders — while 37 added to existing stakes and 23 trimmed.

The largest buyer was Laurion Capital Management, opening a new position worth an estimated $14.3M. The largest seller was Great Point Partners, cutting an estimated $26.9M.

  • 114 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2017, up from 79 in Q3 2017.
  • Funds reported $423M of Concert Pharmaceuticals, Inc. stock for Q4 2017, up 93% quarter-over-quarter.
  • 47 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2017 and 11 closed out, a net change of +36 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q4 2017 was Laurion Capital Management, an estimated $14.3M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q4 2017 was Great Point Partners, an estimated $26.9M sold.

Based on aggregated 13F filings for Q4 2017.